Home Cart Sign in  
Chemical Structure| 1346572-63-1 Chemical Structure| 1346572-63-1

Structure of GSK503
CAS No.: 1346572-63-1

Chemical Structure| 1346572-63-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK-503 is a potent EZH2 inhibitor with potential anticancer activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GSK503

CAS No. :1346572-63-1
Formula : C31H38N6O2
M.W : 526.67
SMILES Code : O=C(C1=CC(C2=CC=C(N3CCN(C)CC3)N=C2)=CC4=C1C(C)=CN4C(C)C)NCC5=C(C)C=C(C)NC5=O
MDL No. :MFCD28405142
InChI Key :HRDQQHUKUIKFHT-UHFFFAOYSA-N
Pubchem ID :67469117

Safety of GSK503

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of GSK503

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CM2005.1 15.9 μM (IC50) 120 hours Inhibited cell growth and colony formation, influenced EZH2-mediated gene transcription and cell cycle PMC6174981
CRMM2 9.3 μM (IC50) 120 hours Inhibited cell growth and colony formation, influenced EZH2-mediated gene transcription and cell cycle PMC6174981
CRMM1 8.5 μM (IC50) 120 hours Inhibited cell growth and colony formation, influenced EZH2-mediated gene transcription and cell cycle PMC6174981
Primary human hepatic stellate cells 10 μM 48 hours To evaluate the effect of GSK503 on TGF-β-induced hepatic stellate cell activation. Results showed that GSK503 significantly reduced fibronectin, α-smooth muscle actin, and collagen 1α1 at both mRNA and protein levels. PMC6282644
VCMsh2THu mouse-derived organoids 5 μM 5 days To investigate the intrinsic transcriptomic changes induced by EZH2 inhibition, revealing 1,542 upregulated and 662 downregulated genes PMC11949072
HCT116 cells 10 μM 72 hours To assess the effect of GSK503 on cell viability in microsatellite unstable cell lines, showing reduced viability PMC11949072
IM9 cells 10 µM 72 hours GSK503 disrupts the RB1-P-S chromatin loop by inhibiting EZH2 activity, restoring RB1 gene expression PMC9522773
RB44 cells 10 µM 72 hours GSK503 disrupts the RB1-P-S chromatin loop by inhibiting EZH2 activity, restoring RB1 gene expression PMC9522773

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57/BL6 mice Carbon tetrachloride (CCl4) or bile duct ligation (BDL)-induced liver fibrosis models Intraperitoneal injection 1.5 mg/mouse 3 times per week for 4 weeks To evaluate the effect of GSK503 on liver fibrosis. Results showed that GSK503 significantly attenuated CCl4 or BDL-induced liver fibrosis, as evidenced by reduced Masson's Trichrome and Sirius red staining, decreased hydroxyproline content, and reduced expression of α-smooth muscle actin and collagen proteins. PMC6282644
Mice Bm12 model Intraperitoneal injection 125 mg/kg/day Daily GSK503 significantly reduced autoantibody production and germinal center formation in the bm12 cGVHD model. PMC7275547
Mice VCMsh2THu mouse model Tail vein injection 200 μg/kg Biweekly for 9 weeks To evaluate the effects of EZH2 inhibition on colonic polyp multiplicity and immune microenvironment, showing significant reduction in polyp multiplicity and increased immune cell abundance PMC11949072
Zebrafish Zebrafish xenograft model Egg water 24 μM Once daily for 5 days Significantly attenuated tumour growth in CM xenografts PMC6174981
Nude mice Orthotopic xenograft model of retinoblastoma Subconjunctival injection 3 µl of 10 µM GSK503 Once daily for 7 days GSK503 significantly reduced tumor volume and weight, suppressing tumor proliferation PMC9522773

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.49mL

1.90mL

0.95mL

18.99mL

3.80mL

1.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories